NASDAQ : ARGX
argenx SE — Key statistics
Healthcare · Biotechnology · Netherlands
Last price 892.87 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 56.37B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 54.04B |
| Enterprise Value | 48.97B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 22, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 62.74M |
| Shares Change (YoY) | -1.31% |
| Shares Change (QoQ) | +0.56% |
| Owned by Insiders (%) | 0.17% |
| Owned by Institutions (%) | 75.65% |
| Float | 62.43M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 30.73 |
| Forward PE | 25.38 |
| PS Ratio | 9.28 |
| Forward PS | 6.99 |
| PB Ratio | 6.52 |
| P/TBV Ratio | 6.74 |
| P/FCF Ratio | 56.61 |
| P/OCF Ratio | 56.37 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 26.56 |
| EV / Sales | 8.43 |
| EV / EBITDA | 26.22 |
| EV / EBIT | 26.38 |
| EV / FCF | 51.39 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.12 |
| Quick Ratio | 4.52 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | 0.05 |
| Interest Coverage | 595.15 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 23.64% |
| Return on Assets (ROA) | 11.63% |
| Return on Invested Capital (ROIC) | 56.96% |
| Return on Capital Employed (ROCE) | 18.94% |
| Weighted Average Cost of Capital (WACC) | 4.02% |
| Revenue Per Employee | $3.18M |
| Profits Per Employee | $1.01M |
| Employee Count | 1,863 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 6.12 |
Taxes
| Measure | Value |
|---|
| Income Tax | 21.57M |
| Effective Tax Rate | 1.14% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.04 |
| 52-Week Price Change | +7.49% |
| 50-Day Moving Average | 940.41 |
| 200-Day Moving Average | 855.06 |
| Relative Strength Index (RSI) | 47.21 |
| Average Volume (20 Days) | 496,030 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.35M |
| Short Previous Month | 1.35M |
| Short % of Shares Out | 2.15% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.31 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 5.92B |
| Gross Profit | 3.54B |
| Operating Income | 1.89B |
| Pretax Income | 1.90B |
| Net Income | 1.88B |
| EBITDA | 1.90B |
| EBIT | 1.89B |
| Earnings Per Share (EPS) | $28.59 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 5.18B |
| Total Debt | 47.00M |
| Net Cash | 5.14B |
| Net Cash Per Share | $81.88 |
| Equity (Book Value) | 8.42B |
| Book Value Per Share | 134.59 |
| Working Capital | 6.49B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 974.19M |
| Capital Expenditures | -4.17M |
| Depreciation & Amortization | 11.45M |
| Net Borrowing | -10.11M |
| Free Cash Flow | 970.03M |
| FCF Per Share | $15.46 |
Margins
| Measure | Value |
|---|
| Gross Margin | 59.84% |
| Operating Margin | 31.94% |
| Pretax Margin | 32.10% |
| Profit Margin | 31.73% |
| EBITDA Margin | 32.14% |
| EBIT Margin | 31.94% |
| FCF Margin | 18.25% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 1.31% |
| Shareholder Yield | 1.31% |
| Earnings Yield | 3.25% |
| FCF Yield | 1.77% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $1,147.35 |
| Price Target Difference | 30.59% |
| Analyst Consensus | Buy |
| Analyst Count | 23 |
| Revenue Growth Forecast (3Y) | 30.57% |
| EPS Growth Forecast (3Y) | 32.61% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |